Lack of galactosylation enhances the pathogenic activity of IgG1 but not IgG2a anti-erythrocyte autoantibodies

Journal of Immunology

Volumn 192, Issue 2, 2014, Pages 581-588

  Ito, Kiyoaki ^a,b   Furukawa, Jun Ichi ^c   Yamada, Kazunori ^a,b   Tran, Ngoc Lan ^a   Shinohara, Yasuro ^c   Izui, Shozo ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; ERYTHROCYTE ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; COMPLEMENT ACTIVATION; COMPLEMENT LECTIN PATHWAY; CONTROLLED STUDY; DISEASE SEVERITY; GALACTOSYLATION; GLYCOSYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIALYLATION; STRUCTURE ANALYSIS;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; COMPLEMENT ACTIVATION; ERYTHROCYTES; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; RECEPTORS, FC;

EID: 84892696203     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302488     Document Type: Article

References (53)

1. Nose, M., and H. Wigzell. 1983. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80: 6632-6636. (Pubitemid 14240149)
2. Wright, A., and S. L. Morrison. 1994. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mousehuman immunoglobulin G1. J. Exp. Med. 180: 1087-1096.
3. Nandakumar, K. S., M. Collin, A. Olsén, F. Nimmerjahn, A. M. Blom, J. V. Ravetch, and R. Holmdahl. 2007. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur. J. Immunol. 37: 2973-2982. (Pubitemid 47578315)
4. Parekh, R. B., R. A. Dwek, B. J. Sutton, D. L. Fernandes, A. Leung, D. Stanworth, T. W. Rademacher, T. Mizuochi, T. Taniguchi, K. Matsuta, et al. 1985. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316: 452-457. (Pubitemid 16238456)
5. Mizuochi, T., J. Hamako, M. Nose, and K. Titani. 1990. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J. Immunol. 145: 1794-1798. (Pubitemid 20336746)
6. Parekh, R., D. Isenberg, G. Rook, I. Roitt, R. Dwek, and T. Rademacher. 1989. A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J. Autoimmun. 2: 101-114.
7. Dubé, R., G. A. Rook, J. Steele, R. Brealey, R. Dwek, T. Rademacher, and J. Lennard-Jones. 1990. Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. Gut 31: 431-434. (Pubitemid 20129442)
8. Holland, M., K. Takada, T. Okumoto, N. Takahashi, K. Kato, D. Adu, A. Ben-Smith, L. Harper, C. O. Savage, and R. Jefferis. 2002. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clin. Exp. Immunol. 129: 183-190.
9. Holland, M., H. Yagi, N. Takahashi, K. Kato, C. O. Savage, D. M. Goodall, and R. Jefferis. 2006. Differential glycosylation of polyclonal IgG, IgG-Fc and IgGFab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim. Biophys. Acta 1760: 669-677.
10. Shinzaki, S., H. Iijima, T. Nakagawa, S. Egawa, S. Nakajima, S. Ishii, T. Irie, Y. Kakiuchi, T. Nishida, M. Yasumaru, et al. 2008. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am. J. Gastroenterol. 103: 1173-1181. (Pubitemid 351677959)
11. Pasek, M., M. Duk, M. Podbielska, R. Sokolik, J. Szechiński, E. Lisowska, and H. Krotkiewski. 2006. Galactosylation of IgG from rheumatoid arthritis (RA) patients-changes during therapy. Glycoconj. J. 23: 463-471. (Pubitemid 44477391)
12. Croce, A., O. Firuzi, F. Altieri, M. Eufemi, R. Agostino, R. Priori, M. Bombardieri, C. Alessandri, G. Valesini, and L. Saso. 2007. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J. Clin. Lab. Anal. 21: 303-314. (Pubitemid 47556810)
13. Van Beneden, K., K. Coppieters, W. Laroy, F. De Keyser, I. E. Hoffman, F. Van den Bosch, B. Vander Cruyssen, M. Drennan, P. Jacques, P. Rottiers, et al. 2009. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann. Rheum. Dis. 68: 1360-1365.
14. Collins, E. S., M. C. Galligan, R. Saldova, B. Adamczyk, J. L. Abrahams, M. P. Campbell, C. T. Ng, D. J. Veale, T. B. Murphy, P. M. Rudd, and O. Fitzgerald. 2013. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxford) 52: 1572-1582.
15. Rook, G. A., J. Steele, R. Brealey, A. Whyte, D. Isenberg, N. Sumar, J. L. Nelson, K. B. Bodman, A. Young, I. M. Roitt, et al. 1991. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J. Autoimmun. 4: 779-794.
16. Bondt, A., M. H. Selman, A. M. Deelder, J. M. Hazes, S. P. Willemsen, M. Wuhrer, and R. J. Dolhain. 2013. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J. Proteome Res. 12: 4522-4531.
17. Rademacher, T. W., P. Williams, and R. A. Dwek. 1994. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc. Natl. Acad. Sci. USA 91: 6123-6127. (Pubitemid 24188295)
18. Kumpel, B. M., Y. Wang, H. L. Griffiths, A. G. Hadley, and G. A. Rook. 1995. The biological activity of human monoclonal IgG anti-D is reduced by betagalactosidase treatment. Hum. Antibodies Hybridomas 6: 82-88. (Pubitemid 3008102)
19. Boyd, P. N., A. C. Lines, and A. K. Patel. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32: 1311-1318. (Pubitemid 26064897)
20. Bond, A., A. Cooke, and F. C. Hay. 1990. Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis. Eur. J. Immunol. 20: 2229-2233. (Pubitemid 20368207)
21. Kuroda, Y., M. Nakata, S. Hirose, T. Shirai, M. Iwamoto, S. Izui, N. Kojima, and T. Mizuochi. 2001. Abnormal IgG galactosylation in MRL-lpr/lpr mice: pathogenic role in the development of arthritis. Pathol. Int. 51: 909-915. (Pubitemid 34175517)
22. Malhotra, R., M.R. Wormald, P.M. Rudd, P. B. Fischer, R. A. Dwek, and R. B. Sim. 1995. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1: 237-243.
23. Nimmerjahn, F., R. M. Anthony, and J. V. Ravetch. 2007. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl. Acad. Sci. USA 104: 8433-8437. (Pubitemid 47175505)
24. Sylvestre, D. L., R. Clynes, M. Ma, H. Warren, M. C. Carroll, and J. V. Ravetch. 1996. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184: 2385-2392. (Pubitemid 27023737)
25. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673. (Pubitemid 44201145)
26. Böhm, S., I. Schwab, A. Lux, and F. Nimmerjahn. 2012. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin. Immunopathol. 34: 443-453.
27. Scallon, B. J., S. H. Tam, S. G. McCarthy, A. N. Cai, and T. S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44: 1524-1534. (Pubitemid 44792756)
28. Baudino, L., Y. Shinohara, F. Nimmerjahn, J.-I. Furukawa, M. Nakata, E. Martínez-Soria, F. Petry, J. V. Ravetch, S.-I. Nishimura, and S. Izui. 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181: 6664-6669.
29. Guhr, T., J. Bloem, N. I. Derksen, M. Wuhrer, A. H. Koenderman, R. C. Aalberse, and T. Rispens. 2011. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS ONE 6: e21246.
30. Leontyev, D., Y. Katsman, X. Z. Ma, S. Miescher, F. Käsermann, and D. R. Branch. 2012. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 52: 1799-1805.
31. de Sá Oliveira, G. G., S. Izui, C. T. Ravirajan, R. A. K. Mageed, P. M. Lydyard, C. J. Elson, and R. N. Barker. 1996. Diverse antigen specificity of erythrocytereactive monoclonal autoantibodies from NZB mice. Clin. Exp. Immunol. 105: 313-320. (Pubitemid 26246952)
32. Shibata, T., T. Berney, L. Reininger, Y. Chicheportiche, S. Ozaki, T. Shirai, and S. Izui. 1990. Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanisms. Int. Immunol. 2: 1133-1141.
33. Azeredo da Silveira, S., S. Kikuchi, L. Fossati-Jimack, T. Moll, T. Saito, J. S. Verbeek, M. Botto, M. J. Walport, M. Carroll, and S. Izui. 2002. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J. Exp. Med. 195: 665-672. (Pubitemid 34259712)
34. Fossati-Jimack, L., A. Ioan-Facsinay, L. Reininger, Y. Chicheportiche, N. Watanabe, T. Saito, F. M. Hofhuis, J. E. Gessner, C. Schiller, R. E. Schmidt, et al. 2000. Markedly different pathogenicity of four immunoglobulin G isotypeswitch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity FcgRIII. J. Exp. Med. 191: 1293-1302. (Pubitemid 30227118)
35. Fossati-Jimack, L., L. Reininger, Y. Chicheportiche, R. Clynes, J. V. Ravetch, T. Honjo, and S. Izui. 1999. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J. Exp. Med. 190: 1689-1696. (Pubitemid 30002350)
36. Baudino, L., F. Nimmerjahn, S. Azeredo da Silveira, E. Martinez-Soria, T. Saito, M. Carroll, J. V. Ravetch, J. S. Verbeek, and S. Izui. 2008. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a-and IgG2b-induced autoimmune hemolytic anemia in mice. J. Immunol. 180: 1948-1953.
37. Meyer, D., C. Schiller, J. Westermann, S. Izui, W. L. W. Hazenbos, J. S. Verbeek, R. E. Schmidt, and J. E. Gessner. 1998. FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood 92: 3997-4002. (Pubitemid 28544311)
38. Park, S. Y., S. Ueda, H. Ohno, Y. Hamano, M. Tanaka, T. Shiratori, T. Yamazaki, H. Arase, N. Arase, A. Karasawa, et al. 1998. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102: 1229-1238. (Pubitemid 28436283)
39. Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. L. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92: 11490-11494. (Pubitemid 26014139)
40. Baudino, L., F. Nimmerjahn, Y. Shinohara, J.-I. Furukawa, F. Petry, J. S. Verbeek, S.-I. Nishimura, J. V. Ravetch, and S. Izui. 2008. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J. Immunol. 181: 4107-4112.
41. Nishimura, S.-I., K. Niikura, M. Kurogochi, T. Matsushita, M. Fumoto, H. Hinou, R. Kamitani, H. Nakagawa, K. Deguchi, N. Miura, et al. 2004. High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDITOF/TOF mass spectrometry. Angew. Chem. Int. Ed. Engl. 44: 91-96. (Pubitemid 40069852)
42. Furukawa, J.-I., Y. Shinohara, H. Kuramoto, Y. Miura, H. Shimaoka, M. Kurogochi, M. Nakano, and S.-I. Nishimura. 2008. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal. Chem. 80: 1094-1101. (Pubitemid 351272343)
43. Kita, Y., Y. Miura, J. Furukawa, M. Nakano, Y. Shinohara, M. Ohno, A. Takimoto, and S.-I. Nishimura. 2007. Quantitative glycomics of human whole serum glycoproteins based on the standardized protocol for liberating N-glycans. Mol. Cell. Proteomics 6: 1437-1445. (Pubitemid 47365441)
44. Miura, Y., Y. Shinohara, J. Furukawa, N. Nagahori, and S. Nishimura. 2007. Rapid and simple solid-phase esterification of sialic acid residues for quantitative glycomics by mass spectrometry. Chemistry 13: 4797-4804. (Pubitemid 46910621)
45. Fujitani, N., J. Furukawa, K. Araki, T. Fujioka, Y. Takegawa, J. Piao, T. Nishioka, T. Tamura, T. Nikaido, M. Ito, et al. 2013. Total cellular glycomics allows characterizing cells and streamlining the discovery process for cellular biomarkers. Proc. Natl. Acad. Sci. USA 110: 2105-2110.
46. Blomme, B., C. Van Steenkiste, P. Grassi, S. M. Haslam, A. Dell, N. Callewaert, and H. Van Vlierberghe. 2011. Alterations of serum protein N-glycosylation in two mouse models of chronic liver disease are hepatocyte and not B cell driven. Am. J. Physiol. Gastrointest. Liver Physiol. 300: G833-G842.
47. Reininger, L., T. Shibata, S. Ozaki, T. Shirai, J.-C. Jaton, and S. Izui. 1990. Variable region sequences of pathogenic anti-mouse red blood cell autoantibodies from autoimmune NZB mice. Eur. J. Immunol. 20: 771-777. (Pubitemid 20167031)
48. Hazenbos, W. L. W., I. A. F. M. Heijnen, D. Meyer, F. M. A. Hofhuis, C. R. Renardel de Lavalette, R. E. Schmidt, P. J. A. Capel, J. G. J. van deWinkel, J. E. Gessner, T. K. van den Berg, and J. S. Verbeek. 1998. Murine IgG1 complexes trigger immune effector functions predominantly via Fc g RIII (CD16). J. Immunol. 161: 3026-3032. (Pubitemid 28425728)
49. Lund, J., N. Takahashi, J. D. Pound, M. Goodall, and R. Jefferis. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc g receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157: 4963-4969. (Pubitemid 126449574)
50. Jassal, R., N. Jenkins, J. Charlwood, P. Camilleri, R. Jefferis, and J. Lund. 2001. Sialylation of human IgG-Fc carbohydrate by transfected rat a2,6-sialyltransferase. Biochem. Biophys. Res. Commun. 286: 243-249. (Pubitemid 32924905)
51. Stadlmann, J., A. Weber, M. Pabst, H. Anderle, R. Kunert, H. J. Ehrlich, H. Peter Schwarz, and F. Altmann. 2009. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 9: 4143-4153.
52. Hulett, M. D., and P. M. Hogarth. 1994. Molecular basis of Fc receptor function. Adv. Immunol. 57: 1-127.
53. Biburger, M., S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, and F. Nimmerjahn. 2011. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932-944.